BacTRL-spike

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name

BacTRL-spike

Accession Number

DB15811

Description

BacTRL-Spike is composed of a bacterial medium with colony-forming-units of live Bifidobacterium longum engineered to deliver synthetic DNA encoding spike protein from SARS-CoV-2 contained by plasmids. The vaccine was developed by Symvivo Corporation. As of June, 2020, the company is pursuing a Phase 1, Randomized, Observer-Blind, Placebo-Controlled Trial (NCT04334980) to test the safety and immunogenicity of the vaccine.

Type

Biotech

Groups

Investigational

Synonyms

Not Available

External IDs

BacTRL-spike

Pharmacology

Indication: Not Available
Contraindications & Blackbox Warnings: Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics: Not Available
Mechanism of action: Not Available
Absorption: Not Available
Volume of distribution: Not Available
Protein binding: Not Available
Metabolism: Not Available
Route of elimination: Not Available
Half-life: Not Available
Clearance: Not Available
Adverse Effects: Learn about our commercial Adverse Effects data.
Learn More
Toxicity: Not Available
Affected organisms: Not Available
Pathways: Not Available
Pharmacogenomic Effects/ADRs: Not Available

Interactions

Drug Interactions: This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions: Not Available